Company
QURE +3.41%uniQure N.V.
Market Cap: $3.04 Billion
USD as of Aug 2, 2026
$QURE +3.41% $QURE Netherlands Healthcare Biotechnology Dutch Healthcare Dutch BiotechnologyuniQure N.V. Market Capitalization Over Time
View HistoryEvolution of uniQure N.V. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Financials
| Last Financial Reports Date | June 30, 2026 |
| Revenue TTM | $18.7 M |
| EBITDA | $-182,916,000 |
| Gross Profit TTM | $-114,707,000 |
| Profit Margin | 89.53% |
| Operating Margin | -872.23% |
| Quarterly Revenue Growth | 11.00% |